Intra-Cellular Financial Statements From 2010 to 2022

ITCI
 Stock
  

USD 57.08  1.23  2.11%   

Intra-Cellular Ther financial statements provide useful quarterly and yearly information to potential Intra-Cellular Ther investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Intra-Cellular Ther financial statements helps investors assess Intra-Cellular Ther's valuation, profitability, and current liquidity needs.
We have found ninety-two available fundamental trends for Intra-Cellular Ther, which can be analyzed and compared to other ratios and to its competitors. Please verify all of Intra-Cellular Ther regular fundamental drivers against the trend between 2010 and 2022 to make sure the company can sustain itself down the road.
Intra-Cellular Ther Market Capitalization is most likely to increase significantly in the upcoming years. The last year's value of Market Capitalization was reported at 4.26 Billion.
  
Refresh
Check Intra-Cellular Ther financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intra-Cellular main balance sheet or income statement drivers, such as Direct Expenses of 8.7 M, Cost of Revenue of 7.1 M or Gross Profit of 81.8 M, as well as many exotic indicators such as Calculated Tax Rate of 0.52, PPandE Turnover of 47.73 or Receivables Turnover of 6.23. Intra-Cellular financial statements analysis is a perfect complement when working with Intra-Cellular Ther Valuation or Volatility modules. It can also supplement various Intra-Cellular Ther Technical models. Please see the analysis of Intra-Cellular Ther Correlation against competitors.

Intra-Cellular Ther Revenues

90.42 Million

Share

Intra-Cellular Ther Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets435.4 M489.9 M294.8 M
Increasing
Slightly volatile
Cash and Equivalents80.4 M93.8 M53.3 M
Increasing
Slightly volatile
Investments334.8 M320 M225.2 M
Increasing
Slightly volatile
Investments Current334.8 M320 M225.2 M
Increasing
Slightly volatile
Deferred Revenue1.8 M1.5 M1.9 M
Decreasing
Slightly volatile
Property Plant and Equipment Net24.3 M22.6 M7.5 M
Increasing
Slightly volatile
Inventory8.5 M7.9 M7.2 M
Increasing
Slightly volatile
Tax Assets244.4 K238.1 K769.9 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables21.7 M20.2 M6.7 M
Increasing
Slightly volatile
Trade and Non Trade Payables7.4 M8.7 M4.7 M
Increasing
Slightly volatile
Total Liabilities77.7 M72 M33.4 M
Increasing
Slightly volatile
Shareholders Equity380.6 M417.9 M263.1 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(392.7 K)(364 K)(234.3 K)
Decreasing
Very volatile
Current Assets419.5 M467.3 M287.7 M
Increasing
Slightly volatile
Assets Non Current24.4 M22.6 M7.8 M
Increasing
Slightly volatile
Current Liabilities57.6 M53.4 M21.5 M
Increasing
Slightly volatile
Liabilities Non Current17.3 M18.7 M12 M
Increasing
Very volatile
Total Debt28.4 M25.4 M24.2 M
Increasing
Slightly volatile
Debt Current6.5 M6.7 M3.9 M
Increasing
Slightly volatile
Debt Non Current18.6 M18.7 M20 M
Decreasing
Very volatile
Shareholders Equity USD380.6 M417.9 M263.1 M
Increasing
Slightly volatile
Cash and Equivalents USD80.4 M93.8 M53.3 M
Increasing
Slightly volatile
Total Debt USD28.4 M25.4 M24.2 M
Increasing
Slightly volatile
Accounts Payable9.4 M8.7 M4.9 M
Increasing
Slightly volatile
Receivables21.7 M20.2 M6.7 M
Increasing
Slightly volatile
Inventories7.3 M7.9 M7.1 M
Increasing
Slightly volatile

Intra-Cellular Ther Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues90.4 M83.8 M19.3 M
Increasing
Slightly volatile
Cost of Revenue7.1 MM2.8 M
Increasing
Slightly volatile
Selling General and Administrative Expense294.1 M272.6 M72.6 M
Increasing
Slightly volatile
Research and Development Expense83.8 M88.8 M61.2 M
Increasing
Slightly volatile
Operating Expenses390 M361.5 M134.8 M
Increasing
Slightly volatile
Interest Expense34 K33.1 K84.7 K
Decreasing
Stable
Income Tax Expense8.6 K5.6 K16.9 K
Decreasing
Very volatile
Consolidated Income(291.6 M)(284.1 M)(113.6 M)
Decreasing
Slightly volatile
Net Income(291.6 M)(284.1 M)(113.6 M)
Decreasing
Slightly volatile
Preferred Dividends Income Statement Impact1.5 M1.5 M1.6 M
Decreasing
Slightly volatile
Net Income Common Stock(291.6 M)(284.1 M)(113.8 M)
Decreasing
Slightly volatile
Weighted Average Shares66.4 M81.3 M40.6 M
Increasing
Slightly volatile
Weighted Average Shares Diluted66.5 M81.3 M40.9 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(291.6 M)(284.1 M)(113.5 M)
Decreasing
Slightly volatile
Revenues USD90.4 M83.8 M19.3 M
Increasing
Slightly volatile
Net Income Common Stock USD(291.6 M)(284.1 M)(113.8 M)
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD(291.6 M)(284.1 M)(113.5 M)
Decreasing
Slightly volatile
Gross Profit81.8 M75.8 M17.9 M
Increasing
Slightly volatile
Operating Income(293.2 M)(285.7 M)(115.8 M)
Decreasing
Slightly volatile
Direct Expenses8.7 MM2.9 M
Increasing
Slightly volatile

Intra-Cellular Ther Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals302.8 M280.7 M(937.4 K)
Increasing
Stable
Net Cash Flow from Financing11.8 M11.5 M115.9 M
Increasing
Stable
Issuance Repayment of Debt Securities 92.4 K90 K3.6 M
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares11.8 M11.5 M112.8 M
Increasing
Stable
Net Cash Flow from Investing302.5 M280.3 M(1.2 M)
Increasing
Stable
Net Cash Flow from Operations(266.4 M)(259.5 M)(100.6 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents34.9 M32.3 M10.7 M
Increasing
Very volatile
Share Based Compensation37.2 M34.5 M13.9 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion425.1 K533.4 K258.3 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share(3.77)(3.5)(2.1964)
Decreasing
Slightly volatile
Earnings per Diluted Share(3.77)(3.5)(2.2057)
Decreasing
Slightly volatile
Earnings per Basic Share USD(3.77)(3.5)(2.1964)
Decreasing
Slightly volatile
Return on Invested Capital(0.65)(0.629)1.7962
Decreasing
Slightly volatile
Gross Margin0.890.9040.9775
Decreasing
Slightly volatile
Profit Margin(3.66)(3.39)(10.3269)
Increasing
Very volatile
EBITDA Margin(3.65)(3.384)(10.2723)
Increasing
Very volatile
Return on Sales(3.66)(3.39)(527)
Decreasing
Stable
Asset Turnover0.150.1430.0752
Decreasing
Stable
Sales per Share1.111.0310.5684
Decreasing
Slightly volatile
Price to Sales Ratio52.0850.7487.2 K
Increasing
Stable
Price to Book Value8.1510.2034.9058
Increasing
Slightly volatile
Debt to Equity Ratio0.190.172(0.3671)
Increasing
Slightly volatile
Current Ratio8.998.75818.1669
Increasing
Very volatile
Free Cash Flow per Share(3.28)(3.198)(1.8139)
Decreasing
Slightly volatile
Book Value per Share6.055.1435.2817
Increasing
Slightly volatile
Tangible Assets Book Value per Share6.986.036.2666
Increasing
Slightly volatile
Total Assets Per Share5.635.98295.5804
Increasing
Slightly volatile
Cash Flow Per Share(3.42)(3.1695)(1.5721)
Decreasing
Slightly volatile
Operating Margin42.4942.7446.7413
Decreasing
Slightly volatile
Calculated Tax Rate0.520.520.5714
Decreasing
Slightly volatile
Receivables Turnover6.236.235.8703
Decreasing
Slightly volatile
Inventory Turnover0.960.961.0537
Decreasing
Slightly volatile
PPandE Turnover47.7344.234120.8738
Decreasing
Stable
Cash and Equivalents Turnover1.181.09970.2485
Increasing
Slightly volatile
Accounts Payable Turnover12.7411.8094.4611
Increasing
Very volatile
Accrued Expenses Turnover4.334.01281.3879
Increasing
Stable
Quick Ratio12.098.105716.7796
Increasing
Stable
Net Current Assets as percentage of Total Assets78.8184.487881.3716
Increasing
Stable
Revenue to Assets0.170.17110.199
Decreasing
Slightly volatile

Intra-Cellular Ther Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(291.6 M)(284.1 M)(113.6 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(291 M)(283.6 M)(113.2 M)
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(291 M)(283.6 M)(113.2 M)
Decreasing
Slightly volatile
Market Capitalization4.6 B4.3 B1.6 B
Increasing
Slightly volatile
Enterprise Value4.5 B4.2 B1.5 B
Increasing
Slightly volatile
Invested Capital332.9 M368.2 M228.6 M
Increasing
Slightly volatile
Average Equity443.8 M517.6 M262.3 M
Increasing
Slightly volatile
Average Assets498.3 M586.8 M293.4 M
Increasing
Slightly volatile
Invested Capital Average372.1 M451.5 M206.9 M
Increasing
Slightly volatile
Tangible Asset Value435.4 M489.9 M294.8 M
Increasing
Slightly volatile
Free Cash Flow(266.7 M)(259.9 M)(100.9 M)
Decreasing
Slightly volatile
Working Capital379.9 M413.9 M267.5 M
Increasing
Slightly volatile
Revenue Per Employee176.6 K163.7 K77.4 K
Decreasing
Stable

Intra-Cellular Fundamental Market Drivers

Short Percent Of Float4.07%
Forward Price Earnings-47.85
Shares Short Prior Month3.85M
Average Daily Volume Last 10 Day942.01k
Average Daily Volume In Three Month900.38k
Date Short Interest29th of April 2022
Fifty Day Average55.54
Two Hundred Day Average48.82

Intra-Cellular Upcoming Events

Upcoming Quarterly Report24th of February 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Intra-Cellular Ther Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Intra-Cellular Ther income statement, its balance sheet, and the statement of cash flows. Intra-Cellular Ther investors use historical funamental indicators, such as Intra-Cellular Ther's revenue or net income, to determine how well the company is positioned to perform in the future. Although Intra-Cellular Ther investors may use each financial statement separately, they are all related. The changes in Intra-Cellular Ther's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intra-Cellular Ther's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Intra-Cellular Ther Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Intra-Cellular Ther. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue1.5 M1.8 M
Cost of RevenueM7.1 M
Revenues83.8 M90.4 M
Revenue to Assets 0.17  0.17 
Revenue Per Employee163.7 K176.6 K
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Intra-Cellular Ther Investors Sentiment

The influence of Intra-Cellular Ther's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intra-Cellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Intra-Cellular Ther Implied Volatility

    
  62.79  
Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

Current Sentiment - ITCI

Intra-Cellular Ther Investor Sentiment

Most of Macroaxis users are currently bullish on Intra-Cellular Ther. What is your judgment towards investing in Intra-Cellular Ther? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Intra-Cellular Ther Correlation against competitors. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.